Chemical: Drug
fentanyl

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for fentanyl

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs10413396 NC_000019.10:g.44309549G>T, NC_000019.9:g.44813702G>T
G > T
SNP
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available CA VA
rs11959113 NC_000005.10:g.148848933G>A, NC_000005.9:g.148228496G>A, XM_005268382.1:c.1175-14764G>A, XM_005268383.1:c.1174+20928G>A, rs61232536, rs74294119
G > A
SNP
No VIP available No Clinical Annotations available VA
rs12211463 NC_000006.11:g.93467158T>G, NC_000006.12:g.92757440T>G, rs59764123
T > G
SNP
No VIP available CA VA
rs12948783 NC_000017.10:g.74499400G>A, NC_000017.11:g.76503318G>A, NG_032852.1:g.3110C>T, NM_024599.5:c.-2185C>T, XM_005257669.1:c.-2602C>T, XM_005257669.2:c.-2602C>T, XM_005257670.1:c.-2185C>T, XM_005257671.1:c.-2286C>T, XM_011525250.1:c.-2286C>T, XM_011525251.1:c.-2127C>T, XM_011525252.1:c.-2185C>T, rs117129397, rs60624663
G > A
G > T
SNP
No VIP available No Clinical Annotations available VA
rs13422094 NC_000002.11:g.22181114T>C, NC_000002.12:g.21958242T>C, XR_939813.1:n.185+6266T>C
T > C
SNP
No VIP available CA VA
rs1799971 NC_000006.11:g.154360797A>G, NC_000006.12:g.154039662A>G, NG_021208.1:g.34162A>G, NM_000914.4:c.118A>G, NM_001008503.2:c.118A>G, NM_001008504.3:c.118A>G, NM_001008505.2:c.118A>G, NM_001145279.3:c.397A>G, NM_001145280.3:c.-11+28644A>G, NM_001145281.2:c.47+29103A>G, NM_001145282.2:c.118A>G, NM_001145283.2:c.118A>G, NM_001145284.3:c.118A>G, NM_001145285.2:c.118A>G, NM_001145286.2:c.118A>G, NM_001285522.1:c.118A>G, NM_001285523.1:c.118A>G, NM_001285524.1:c.397A>G, NP_000905.3:p.Asn40Asp, NP_001008503.2:p.Asn40Asp, NP_001008504.2:p.Asn40Asp, NP_001008505.2:p.Asn40Asp, NP_001138751.1:p.Asn133Asp, NP_001138754.1:p.Asn40Asp, NP_001138755.1:p.Asn40Asp, NP_001138756.1:p.Asn40Asp, NP_001138757.1:p.Asn40Asp, NP_001138758.1:p.Asn40Asp, NP_001272451.1:p.Asn40Asp, NP_001272452.1:p.Asn40Asp, NP_001272453.1:p.Asn133Asp, NR_104348.1:n.252A>G, NR_104349.1:n.252A>G, NR_104350.1:n.252A>G, NR_104351.1:n.252A>G, XM_005267002.1:c.304A>G, XM_006715497.2:c.304A>G, XM_011535849.1:c.397A>G, XP_005267059.1:p.Asn102Asp, XP_006715560.1:p.Asn102Asp, XP_011534151.1:p.Asn133Asp, XR_245534.1:n.304A>G, XR_245535.1:n.304A>G, XR_245536.1:n.304A>G, XR_245537.1:n.304A>G, rs17181017, rs52818856, rs61596185
A > -
A > G
SNP
N40D
No VIP available No Clinical Annotations available VA
rs2076222 NC_000001.10:g.209791929G>T, NC_000001.11:g.209618584G>T, NG_007116.1:g.38892C>A, NM_000228.2:c.2777C>A, NM_001017402.1:c.2777C>A, NM_001127641.1:c.2777C>A, NP_000219.2:p.Ala926Asp, NP_001017402.1:p.Ala926Asp, NP_001121113.1:p.Ala926Asp, XM_005273124.1:c.2777C>A, XM_005273124.3:c.2777C>A, XP_005273181.1:p.Ala926Asp, rs58828090
G > T
SNP
A926D
No VIP available No Clinical Annotations available VA
rs2473967 NC_000006.11:g.113479335G>T, NC_000006.12:g.113158133G>T, rs74295796
G > T
SNP
No VIP available CA VA
rs2835859 NC_000021.8:g.39018162T>C, NC_000021.9:g.37645860T>C, NG_029892.2:g.275534A>G, NM_002240.4:c.947-20376A>G, XM_011529558.1:c.947-20376A>G, XM_011529559.1:c.947-20376A>G, rs57686640
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2884129 NC_000010.10:g.17585149T>G, NC_000010.11:g.17543150T>G
T > G
SNP
No VIP available CA VA
rs2952768 NC_000002.11:g.208494234T>C, NC_000002.12:g.207629510T>C, rs57113745, rs74270034
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3845446 NC_000001.10:g.181766437T>C, NC_000001.11:g.181797301T>C, NM_000721.3:c.6270+443T>C, NM_001205293.1:c.6399+443T>C, NM_001205294.1:c.6213+443T>C, XM_005245477.1:c.6258+443T>C, XM_011509971.1:c.6342+443T>C, rs386587547, rs60661707
T > C
SNP
No VIP available No Clinical Annotations available VA
rs7104613 NC_000011.10:g.14058384C>T, NC_000011.9:g.14079931C>T, NM_006108.3:c.479+16730C>T, NW_003871075.1:g.116468C>T, rs60203831
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7757130 NC_000006.11:g.113317262C>A, NC_000006.12:g.112996060C>A, XR_942887.1:n.973-1377C>A
C > A
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs9384179 NC_000006.11:g.154421057G>A, NC_000006.12:g.154099922G>A, NG_021208.1:g.94422G>A, NM_000914.4:c.1164+8450G>A, NM_001008503.2:c.1164+8450G>A, NM_001145279.3:c.1443+8450G>A, NM_001145280.3:c.864+8450G>A, NM_001145281.2:c.921+8450G>A, NM_001145282.2:c.1164+8450G>A, NM_001145283.2:c.1165-8094G>A, NM_001145284.3:c.1165-7826G>A, NM_001145285.2:c.1165-7694G>A, NM_001145286.2:c.1165-7543G>A, NM_001145287.2:c.864+8450G>A, NM_001285522.1:c.291-18761G>A, NM_001285524.1:c.1443+8450G>A, NM_001285526.1:c.864+8450G>A, NR_104348.1:n.1407+5604G>A, NR_104349.1:n.1407+5604G>A, NR_104350.1:n.945+8450G>A, NR_104351.1:n.1407+5604G>A, XM_005267003.1:c.864+8450G>A, XM_011535849.1:c.1443+8450G>A, XM_011535859.1:c.864+8450G>A, XM_011535860.1:c.864+8450G>A, XM_011535861.1:c.864+8450G>A, XR_245534.1:n.1459+5604G>A, XR_245535.1:n.1459+5604G>A, XR_245536.1:n.1459+5604G>A, XR_245537.1:n.997+8450G>A
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Fentanila [INN-Spanish]
  • Fentanyl citrate
  • Fentanylum [INN-Latin]
  • fentanyl
Trade Names
  • Actiq
  • Duragesic
  • Duragesic-100
  • Durogesic
  • Fentanest
  • Fentanil
  • Nasalfent
  • Pentanyl
  • Phentanyl
  • Rapinyl
  • Sentonil
  • Sublimaze
Brand Mixture Names
  • Innovar Injection (droperidol + fentanyl citrate)

PharmGKB Accession Id

PA449599

Type(s):

Drug

Description

A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)

Source: Drug Bank

Indication

For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Source: Drug Bank

Pharmacology

Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

Source: Drug Bank

Food Interaction

Avoid alcohol.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.

Source: Drug Bank

Protein Binding

80-85%

Source: Drug Bank

Absorption

Bioavailability is 92% following transdermal administration and 50% following buccal administration.

Source: Drug Bank

Half-Life

7 (range 3-12) hours

Source: Drug Bank

Toxicity

Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.

Source: Drug Bank

Route of Elimination

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.

Source: Drug Bank

Volume of Distribution

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H28N2O

Source: Drug Bank

Isomeric SMILES

CCC(=O)N(c1ccccc1)C2CCN(CC2)CCc3ccccc3

Source: OpenEye

Canonical SMILES

CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

336.4705

Source: Drug Bank

Monoisotopic Molecular Weight

336.220163528

Source: Drug Bank

SMILES

CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
OPRD1 (source: Drug Bank)
OPRK1 (source: Drug Bank)
OPRM1 (source: Drug Bank)

Drug Interactions

Interaction Description
amiodarone - fentanyl Possible bradycardia, hypotension (source: Drug Bank)
amiodarone - fentanyl Possible bradycardia, hypotension (source: Drug Bank)
amprenavir - fentanyl The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
amprenavir - fentanyl The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl. (source: Drug Bank)
cimetidine - fentanyl Increases the effect of the narcotic (source: Drug Bank)
cimetidine - fentanyl Increases the effect of the narcotic (source: Drug Bank)
fentanyl - amiodarone Possible bradycardia, hypotension (source: Drug Bank)
fentanyl - amprenavir The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fentanyl - cimetidine Cimetidine increases the effect of the narcotic (source: Drug Bank)
fentanyl - fluconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fentanyl - fosamprenavir The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fentanyl - indinavir The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fentanyl - itraconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fentanyl - ketoconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fentanyl - naltrexone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
fentanyl - nelfinavir The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fentanyl - rifampin Rifampin reduces levels and efficacy of fentanyl/alfentanyl (source: Drug Bank)
fentanyl - ritonavir Ritonavir increases the effect and toxicity of fentanyl/alfentanyl (source: Drug Bank)
fentanyl - saquinavir The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fentanyl - voriconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fluconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fluconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fosamprenavir - fentanyl The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
fosamprenavir - fentanyl The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl. (source: Drug Bank)
indinavir - fentanyl The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
indinavir - fentanyl The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl. (source: Drug Bank)
itraconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
itraconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
ketoconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
ketoconazole - fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
naltrexone - fentanyl Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
naltrexone - fentanyl Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
nelfinavir - fentanyl The protease inhibitor increases the effect and toxicity of fentanyl (source: Drug Bank)
nelfinavir - fentanyl The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl. (source: Drug Bank)
rifampin - fentanyl Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
rifampin - fentanyl Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
telithromycin - fentanyl Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
tranylcypromine - fentanyl Possible increased risk of serotonin syndrome. (source: Drug Bank)
triprolidine - fentanyl The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
triprolidine - fentanyl The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
voriconazole - fentanyl Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to fentanyl: 29

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study identifies candidate loci associated with postoperative fentanyl requirements after laparoscopic-assisted colectomy. Pharmacogenomics. 2015. Mieda Tsutomu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA psychiatry. 2015. Oslin David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. Pharmacogenetics and genomics. 2015. Foulds James A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British journal of clinical pharmacology. 2014. Mouly S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses. PloS one. 2015. Yoshida Kaori, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. The pharmacogenomics journal. 2014. Chidambaran V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics. 2014. Matic Maja, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Pharmacogenomics. 2014. Zhao Qin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and genomics. 2014. Barratt Daniel T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA : the journal of the American Medical Association. 2013. Wachman Elisha M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Molecular psychiatry. 2012. Nishizawa D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer. 2012. Liu Yu-Chang, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple Loci modulate opioid therapy response for cancer pain. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Galvan Antonella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regulatory toxicology and pharmacology : RTP. 2011. Volpe Donna A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of clinical pharmacology. 2011. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011. Meyer Markus R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva anestesiologica. 2011. Zhang W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain. 2009. Fukuda Kenichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. British journal of anaesthesia. 2009. Ginosar Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain. 2008. Landau Ruth, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical pharmacology and therapeutics. 2008. Campa D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of general psychiatry. 2008. Anton Raymond F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. European journal of clinical pharmacology. 2008. Saari Teijo I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007. Reyes-Gibby Cielito C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clinical pharmacology and therapeutics. 2007. Park H-J, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0781-7240-55
DrugBank:
DB00813
ChEBI:
119915
KEGG Drug:
D00320
PubChem Compound:
3345
PubChem Substance:
153132
46506372
IUPHAR Ligand:
1626
Drugs Product Database (DPD):
2240434
BindingDB:
50008984
ChemSpider:
3228
Therapeutic Targets Database:
DAP000072
FDA Drug Label at DailyMed:
ca7a8abd-9301-40f5-9300-6398f4d467b3

Clinical Trials

These are trials that mention fentanyl and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.